eMedicine Specialties > Emergency Medicine > Warfare - Chemical, Biological, Radiological, Nuclear and Explosives

CBRNE - Q Fever

Author: Geofrey Nochimson, MD, Consulting Staff, Department of Emergency Medicine, Sentara Careplex Hospital
Contributor Information and Disclosures

Updated: Sep 25, 2008

Introduction

Background

First described in Australia in 1935, Q fever is a rickettsial disease with acute and chronic stages. Q fever differs from other rickettsial diseases in that it is caused by inhalation of infected particles, not by a tick bite. Because Q fever is transmitted via an inhalational route, it can be used as a biological warfare agent. The Centers for Disease Control and Prevention (CDC) classifies Q fever as a Category B agent.

Pathophysiology

The respiratory system is the main organ system affected, although GI and cardiac systems also are affected. Incubation period varies from 9-40 days, with an average range of 18-21 days.

Frequency

United States

Frequency is difficult to ascertain even though Q fever is a reportable disease in all US states except Delaware, Iowa, Oklahoma, Vermont, and West Virginia. In 2005, 136 cases were reported to the CDC; in 2006, 169 cases were reported. Dairy and slaughterhouse workers are most at risk. In 2006, the incidence was reported to be 0.06 per 100,000 population.

International

Incidence of Q fever is worldwide and varies in frequency and presentation from country to country. A recent outbreak occurred in the Netherlands in 2008.1 From January to July, 660 cases have been reported. This is the second outbreak to occur in the Netherlands since 2007. At this time, the cause is still unknown.

Mortality/Morbidity

The mortality rate with acute infection is reportedly as high as 2.4% but generally is less than 1%.

Sex

Males are affected more than females. Of the 169 cases reported to the CDC in 2006, 127 were in males and 42 were in females.

Age

Adults are affected more than children. The highest age range is between 40 and 64 years.

Clinical

History

  • Patients initially present with influenzalike symptoms.
  • Respiratory symptoms appear 4-5 days after initial onset of illness (most prominently a dry nonproductive cough and pleuritic chest pain).
  • Symptoms of Q fever include the following:
    • Fever
    • Severe headache
    • Myalgias
    • Anorexia
    • Cough
    • Pleuritic chest pain
    • Sweats
    • Chills
    • Nausea, vomiting, and diarrhea (rare)

Physical

Often in acute Q fever, specific findings may not exist. In chronic Q fever, findings consistent with endocarditis and hepatitis more frequently are found.

  • Findings in endocarditis include the following:
    • Vegetations on any valve (although aortic and prosthetic valves are favored)
    • Clubbing of digits
    • Hepatomegaly and splenomegaly in approximately one half of patients
    • Arterial emboli in approximately one third of patients
    • Purpuric rash in approximately 20% of patients
  • Findings in hepatitis include the following:
    • Fever
    • Malaise
    • Hepatomegaly with right upper quadrant pain
    • Jaundice (occasional)
  • Aseptic meningitis/encephalitis occurs in approximately 1% of acute and chronic Q fever cases.

Causes

Coxiella burnetii, a pleomorphic coccobacillus that is much smaller than other rickettsias, is the etiologic agent of Q fever. Humans are infected by inhalation of C burnetii. Why chronic Q fever develops in certain patients is unknown.

  • Q fever is extremely virulent; 1 bacterium can cause infection.
  • Q fever is extremely resistant to inactivation; it can survive for months in dust and feces particles.
  • Tick species, naturally infected, infect domestic and small mammals (eg, cats).
  • C burnetii localizes in the mammary glands, uterus, and feces of these animals. Exposure to feces can lead to disease.
  • Laboratory outbreaks have occurred. Only 1 case of documented human-to-human transmission exists.
  • C burnetii exists in 2 antigenic states, phase I (virulent) and phase II (avirulent).

More on CBRNE - Q Fever

Overview: CBRNE - Q Fever
Differential Diagnoses & Workup: CBRNE - Q Fever
Treatment & Medication: CBRNE - Q Fever
Follow-up: CBRNE - Q Fever
References

References

  1. Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoff G, Timen A, et al. Large ongoing Q fever outbreak in the south of The Netherlands, 2008. Euro Surveill. Jul 31 2008;13(31):[Medline][Full Text].

  2. Aitken ID, Bogel K, Cracea E, et al. Q fever in Europe: current aspects of aetiology, epidemiology, human infection, diagnosis and therapy. Infection. 1987;15(5):323-7. [Medline].

  3. CDC. Q fever outbreak--Germany, 1996. MMWR Morb Mortal Wkly Rep. Jan 17 1997;46(2):29-32. [Medline].

  4. CDC. Q Fever: Diagnosis & Laboratory Guidance For Clinicians. CDC. Available at http://emergency.cdc.gov/agent/qfever/clinicians/diagnosis.asp. Accessed September 4, 2008.

  5. Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. May 2006;12 Suppl 3:12-24.

  6. Madariaga MG, Rezai K, Trenholme GM. Q fever: a biological weapon in your backyard. Lancet Infect Dis. Nov 2003;3(11):709-21. [Medline].

  7. Mann JS, Douglas JG, Inglis JM. Q fever: person to person transmission within a family. Thorax. Dec 1986;41(12):974-5. [Medline].

  8. Marrie TJ. Coxiella burnetii (Q fever). In: Principles and Practice of Infectious Diseases. 4th ed. Churchill Livingstone; 1995:1727-35.

  9. Marrie TJ. Q fever pneumonia. Curr Opin Infect Dis. Apr 2004;17(2):137-42. [Medline].

  10. MMWR. Q fever--California, Georgia, Pennsylvania, and Tennessee, 2000-2001. MMWR Morb Mortal Wkly Rep. Oct 18 2002;51(41):924-7. [Medline].

  11. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. Feb 25 2006;367(9511):679-88. [Medline].

  12. Raoult D, Marrie TJ. Q fever. In: Clinical Infectious Diseases. Oxford University Press; 1995:489-96.

  13. Warfare Borden Institute, Walter Reed Army Medical Center. Textbook of Military Medicine Medical Aspects of Chemical and Biological Warfare.

Further Reading

Keywords

Q fever, query fever, Coxiella burnetii, C burnetii, rickettsial infection, rickettsial disease, biological warfare, biological warfare agent, category B agent

Contributor Information and Disclosures

Author

Geofrey Nochimson, MD, Consulting Staff, Department of Emergency Medicine, Sentara Careplex Hospital
Geofrey Nochimson, MD is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Nothing to disclose.

Medical Editor

Robert L Norris, MD, Associate Professor, Department of Surgery; Chief, Division of Emergency Medicine, Stanford University Medical Center
Robert L Norris, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, California Medical Association, International Society of Toxinology, Society for Academic Emergency Medicine, and Wilderness Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Jeter (Jay) Pritchard Taylor III, MD, Compliance Officer, Attending Physician Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Richland Memorial Hospital, University of South Carolina
Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine
Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Association of Military Surgeons of the US
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.